文献库搜索 | GeneLibs

Patel(HV),Smith(AE),Chan(S),Gasendo(JG),Jo... Cancer Res 2026-05-04

...KRAS-mutant non-small cell lung cancer (NSCLC) and colorectal cancer models as a frequent, nongenetic driver of inherent...

Kim(HM),Jeong(K),Jeong(J),Jin(SM),Yoo(J),Y... Cancer Cell Int 2026-02-09

...Kras and lack E-cadherin and p53. Tumors were generated in syngeneic mice by subcutaneous injection of Tcon cells into t...

He(Q),Guo(XB),Chen(YR),Gao(XX),Zhao(J),Zho... J Thorac Dis 2026-01-31

...KRAS mutant NSCLC, patients with KRAS G12C mutations exhibited longer PFS (19.9 vs. 10.3 months, P=0.71) and OS (NR vs. ...

Sadeghi(H),Kohkalani(M),Seyyed Rezaei(SA),... Biomed Pharmacother 2026-03-00

...KRAS, TP53, CDKN2A, and SMAD4-drive abnormal signaling through the MAPK/ERK, PI3K/AKT, and NF-κB pathways, among others,...

Gao(L),Li(J),Wang(F),Miao(L),Liu(S),Yang(Z... AME Case Rep None

...KRAS and TP53 genes mutation. This tumor is highly aggressive, 75.0% (6/8) of the cases recurred or dead within one year...

Quevrin(C),Mondini(M),Meziani(L),Gerbe-De-... J Immunother Cancer 2026-07-17

...KRAS enhances DNA damage repair, replication stress tolerance, redox buffering, and ferroptosis defense. The KRAS-NRF2-5...

Nguyen(DT),Meneses(KM),Zhang(C),Prieto(LI)... Cell Rep 2026-07-28

...Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent...

Ajay(N),Anilkumar(AS),Veerabathiran(R) Semin Oncol 2026-08-00

...KRAS, PI3K-AKT-mTOR, EGFR, p53, PTEN, and LKB1-AMPK, that control glucose, amino acid, lipid, nucleotide, and mitochondr...

Mehmood(MS),Noor(M),Meraj(S),Hassan(A),Ali... Discov Oncol 2026-07-18

...KRAS, TP53, SMAD4, and CDKN2A as high-value targets, while simultaneously revealing synthetic lethal interactions that w...

Saleh(M),Akil(A),Chehade(L),Diab(T),Hassan... Clin Med Insights Oncol None

...KRAS mutations in 42.9% (n=70/163 tested) and BRAF mutations in 7.0% (n=9/128 tested). Smoking (HR = 2.58, p = 0.007) an...